Pharmacy

There’s no silver bullet for migraine treatments, but treatments are getting more precise as we learn more about the cause of migraines.

Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.

Industry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.

Drug shortages take a toll, especially on emergency department patients.

Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems. Here’s what healthcare providers should do about the issue.

At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.

A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.

Probuphine implant could be a new option for addicts if obstacles, such as price, don’t get in the way.

Although the diabetes pipeline is not large, we continue to have progress in meeting the unmet needs of patients with diabetes.

Participants in a new CMS payment program will attempt to improve the effectiveness and efficiency of cancer care delivery. Here’s how.

Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.

As pharmaceutical companies of all sizes continue to adapt to the ongoing internal and external pressures of the new health economy, it remains imperative that strategy maintain distinct capabilities to position the company ahead of its competitors.

Insights from the 2016 edition of the largest gathering in specialty pharmacy.

Hep C virus testing supports value of diagnostics in precision medicine.

A new study examines payer payment shifts for opioids.

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.

Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.

Hospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.

Like any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications-just a year after Medicare Part D extended its coverage to include them in 2012-has some wondering why so many of these drugs are being prescribed.

New analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.

Two presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.

AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.

IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.

F. Randy Vogenberg, PhD, partner, Access Market Intelligence, and cofounder National Institute of Collaborative Healthcare, Greenville, S.C., shares insight from AMCP.

At AMCP 2016, presenters identified five types of alternative payment models, and shared why pharmacists play a key role.

Value-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”

AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching

: Providers and health plans aren’t the only industry groups affected by the shift to value-based care. It’s time for pharma to get in on the action.

A presenter at the AMCP Annual Meeting examines two different tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.

At the AMCP Annual Meeting, three panelists shared real-world examples of technology that is improving patient engagement, adherence, and outcomes